Optimizing the timing of chemotherapy for mobilizing autologous blood hematopoietic progenitor cells

被引:21
作者
Hicks, Michelle L. [1 ]
Lonial, Sagar [1 ]
Langston, Amelia [1 ]
Flowers, Christopher [1 ]
Roback, John D. [1 ]
Smith, Kenneth J. [1 ]
Sai, Sarah Mossavi [1 ]
Teagarden, Diane [1 ]
Hamilton, Ellie S. [1 ]
Waller, Edmund K. [1 ]
机构
[1] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA 30322 USA
关键词
D O I
10.1111/j.1537-2995.2007.01164.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
BACKGROUND: Postchemotherapy mobilization results were reviewed in patients undergoing apheresis before planned autologous hematopoietic progenitor cell (HPC) transplantation to improve the timing of collection procedures. STUDY DESIGN AND METHODS: A total of 135 attempts to collect autologous HPC were studied in 132 unique patients with lymphoid malignancies (nonHodgkin's lymphoma, multiple myeloma, and Hodgkin's disease). Chemotherapy mobilization regimens included cyclophosphamide (n = 59), ICE (n = 46), or other regimens (n = 30). Granulocyte-colony-stimulating factor (CSF) was administered once daily at a dose of 5 pg per kg starting 2 days after the last dose of chemotherapy; granulocyte-macrophage-CSF was added at a daily dose of 5 pg per kg 6 days later. Apheresis was initiated when the blood CD34+ content was more than 20 per pL. RESULTS: In an initial cohort of 37 patients, 27 percent required apheresis during the weekend. An optimized timing for chemotherapy mobilization was developed based on retrospective data; prospective implementation of the new algorithm reduced the incidence of weekend apheresis to 13 percent in the subsequent 98 consecutive patients (p < 0.05). A median of 9 x 10(6) (range, 0.4 x 10(6)-96 x 10(6)) CD34+ cells per kg was collected from the entire cohort of 135 patients after a mean of 1.8 days of apheresis. Apheresis was initiated following a median (+/- SD) of 10 +/- 2.7 days of cytokines. CONCLUSION: In the majority of patients, the first day of apheresis occurred 11 to 13 days after the last dose of chemotherapy with a variety of different chemotherapy regimens. Administering the last dose of chemotherapy on Thursday or Friday versus Monday, Tuesday, or Wednesday was associated with a 77 percent lower incidence in the frequency of weekend apheresis collections (p < 0.001).
引用
收藏
页码:629 / 635
页数:7
相关论文
共 19 条
[1]  
APPELBAUM FR, 1988, SEMIN HEMATOL, V25, P16
[2]   Guideline for the flow cytometric enumeration of CD34+ haematopoietic stem cells [J].
Barnett, D ;
Janossy, G ;
Lubenko, A ;
Matutes, E ;
Newland, A ;
Reilly, JT .
CLINICAL AND LABORATORY HAEMATOLOGY, 1999, 21 (05) :301-308
[3]   CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. [J].
Coiffier, B ;
Lepage, E ;
Brière, J ;
Herbrecht, R ;
Tilly, H ;
Bouabdallah, R ;
Morel, P ;
Van den Neste, E ;
Salles, G ;
Gaulard, P ;
Reyes, F ;
Gisselbrecht, C .
NEW ENGLAND JOURNAL OF MEDICINE, 2002, 346 (04) :235-242
[4]  
Cortes J, 1999, CLIN CANCER RES, V5, P2491
[5]   The use of AMD3100 plus G-CSF for autologous hematopoietic progenitor cell mobilization is superior to G-CSF alone [J].
Flomenberg, N ;
Devine, SM ;
DiPersio, JF ;
Liesveld, JL ;
McCarty, JM ;
Rowley, SD ;
Vesole, DH ;
Badel, K ;
Calandra, G .
BLOOD, 2005, 106 (05) :1867-1874
[6]   An evaluation of predictive factors for CD34+cell harvest yields from patients mobilized with chemotherapy and growth factors [J].
Ford, CD ;
Chan, KJ ;
Reilly, WF ;
Petersen, FB .
TRANSFUSION, 2003, 43 (05) :622-625
[7]   Efficacy of single-dose pegfilgrastim after chemotherapy for the mobilization of autologous peripheral blood stem cells in patients with malignant lymphoma or multiple myeloma [J].
Kroschinsky, Frank ;
Hoelig, Kristina ;
Platzbecker, Uwe ;
Poppe-Thiede, Kirsten ;
Ordemann, Rainer ;
Blechschmidt, Matthias ;
Oelschlaegel, Uta ;
Schaich, Markus ;
Haenel, Mathias ;
Bornhaeuser, Martin ;
Ehninger, Gerhard .
TRANSFUSION, 2006, 46 (08) :1417-1423
[8]   DTPACE: An effective, novel combination chemotherapy with thalidomide for previously treated patients with myeloma [J].
Lee, CK ;
Barlogie, B ;
Munshi, N ;
Zangari, M ;
Fassas, A ;
Jacobson, J ;
van Rhee, F ;
Cottler-Fox, M ;
Muwalla, F ;
Tricot, G .
JOURNAL OF CLINICAL ONCOLOGY, 2003, 21 (14) :2732-2739
[9]   A randomized trial comparing the combination of granulocyte-macrophage colony-stimulating factor plus granulocyte colony-stimulating factor versus granulocyte colony-stimulating factor for mobilization of dendritic cell subsets in hematopoietic progenitor cell products [J].
Lonial, S ;
Hicks, M ;
Rosenthal, H ;
Langston, A ;
Redei, I ;
Torre, C ;
Duenzl, M ;
Feinstein, B ;
Cherry, J ;
Waller, EK .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2004, 10 (12) :848-857
[10]   High dose chemotherapy without hematopoietic cell support for the treatment of refractory lymphoma [J].
Lonial, S ;
Jones, TW ;
Devine, S ;
Winton, EF ;
Heffner, LT ;
Smith, KJ ;
Yeager, AM ;
Waller, EK .
LEUKEMIA & LYMPHOMA, 2000, 36 (5-6) :497-502